Humacyte, Inc.
Humacyte is a regenerative medicine company developing bioengineered vascular grafts with minimal political/regulatory exposure and no meaningful government dependence.
BusinessWhat HUMA does
Humacyte develops off-the-shelf, bioengineered human vascular grafts for vascular access, peripheral vascular disease, and congenital heart disease applications. Revenue is primarily from product sales and development partnerships; the company is pre-commercial or early-stage commercial with limited revenue scale.
12 months past · 3 months futureHUMA activity timeline
Lifetime Government AwardsHUMA federal contracts
HUMA doesn't hold direct federal contracts.
Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.
Congressional TradesWho in Congress is trading HUMA
Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock
No Form 4 activity recorded in the last 180 days.
Bills to WatchLegislation flagged by our analysis
Political ProfileWhere HUMA sits in Washington
Humacyte has no active lobbying, no campaign donations, and no legislative naming. Stock movement is driven by clinical trial results and FDA decisions, not political events. Senator Tuberville's sales activity reflects general portfolio rebalancing, not company-specific political exposure.
Regulatory ExposureThreats & opportunities
Regulatory threats
- FDA approval delays or additional clinical trial requirements
- Medicare/Medicaid reimbursement denial or restrictive coding
Regulatory opportunities
- FDA breakthrough device designation expansion
- Medicare coverage expansion for regenerative medicine products
Live signals + predictions for HUMA — for Founders
The free page above gives you the public record. Members see the real-time intelligence layer on top of it:
- Live 7-layer signal scores when Congress trades HUMA
- Bill Pass Index v2 odds for every bill on the watch list
- Iron Triangle alerts (committee × donor × trade)
- SEC Form 4 cluster detection (CEO + CFO + director buys)
- Whale-Opportunity expected-value ranking
- Custom watchlist alerts via email + Discord